ChartMillAugust 6, 2026 at 4:52 PM NY2 Months Ago
Denali Therapeutics (NASDAQ:DNLI) Drops as Q2 AVLAYAH Revenue Misses Estimates
Denali Therapeutics (DNLI) stock fell 12% after Q2 revenue miss. AVLAYAH sales low, but Q3 guidance of $10-12M signals acceleration.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: ChartMill
